Menu
Curie Logo
Donate
  • Home

Clinical trials

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Breast cancer
    Paris, Saint-Cloud
    TOPOLOGY
    A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

    FRANCOIS-CLEMENT BIDARD

  • Cancers gynécologiques
    Paris
    GLORIOSA
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA).

    MANUEL RODRIGUES

  • Cancers gynécologiques
    Saint-Cloud
    AFTERGYN
    Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase (AFTERGYN)

    DIANA BELLO ROUFAI

  • Cancers urogénitaux
    Paris, Saint-Cloud
    CAAA617D12302
    A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.

    CAPUCINE RICHARD

  • Paris
    DF1001-001
    A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

    EMANUELA ROMANO

  • Paris
    MCLA-158-CL01
    Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.

    EDITH BORCOMAN

  • Myélome
    Saint-Cloud
    R5458-ONC-2245
    An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; anti-;BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab,;Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory;Multiple Myeloma (LINKER-MM3).

    Cyrine ELLOUZ

  • Lung cancer
    Paris
    DS1062-A-U303/ TROPION-Lung07
    A Randomized Phase 3 Study of Datopotamab Deruxtecan;(Dato-DXd) and Pembrolizumab, with or Without Platinum;Chemotherapy, in Subjects with No Prior Therapy for;Advanced or Metastatic PD-L1 TPS <50% Non-squamous;Non-small Cell Lung Cancer Without Actionable Genomic;Alterations;(TROPION-Lung07)

    NICOLAS GIRARD

  • Cancers gynécologiques
    Saint-Cloud
    DS6000-109
    A Phase 2/3, Multicenter, Randomized Study of Raludotatug;Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate,;in Subjects with Platinum-resistant, High-grade Ovarian, Primary;Peritoneal, or Fallopian Tube Cancer.

    DIANA BELLO ROUFAI

  • Eye tumors / Uveal melanoma
    Paris
    IDE 196-002
    IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator·s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).

    SOPHIE PIPERNO-NEUMANN

  • Cancers gynécologiques
    Paris
    VS-6766-301 (RAMP 301)
    A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus;InvestigatorÀs Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).

    MANUEL RODRIGUES

  • ENT/Head and Neck Cancers
    Paris
    219885 GALAXIES H&N-202
    A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

    CHRISTOPHE LE TOURNEAU

  • Colorectal cancer
    Saint-Cloud
    ADAGE - Prodige 34
    Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.

  • Sarcomas
    Paris
    ADCT-601-102
    A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

  • Saint-Cloud
    AIPAC
    AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

    ETIENNE BRAIN

  • Lung cancer
    Paris
    AK112-301-HARMONi
    A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.

    NICOLAS GIRARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-2
    Analysis of Circulating Tumor Markers in Blood

    FRANCOIS-CLEMENT BIDARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-4 (IC 2020-11)
    Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

    FRANCOIS-CLEMENT BIDARD

  • Paris, Saint-Cloud
    ALCYTA (IC 2020-12)
    Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA

    NICOLAS GIRARD

  • Saint-Cloud
    ALPHABET
    Randomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    AMEBICA - Prodige 38
    Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours.

  • Saint-Cloud
    AML LI-1
    A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME

    JACQUES VARGAFTIG

  • Saint-Cloud
    APACaP
    Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

  • Saint-Cloud
    AcSé Pembrolizumab
    Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types.

    CAROLE SOUSSAIN

  • Saint-Cloud
    AcSé Vemurafenib
    Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

    ETIENNE BRAIN

  • Sarcomas
    Paris
    BFR ESS 01
    Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS

    SOPHIE PIPERNO-NEUMANN

  • Paris
    BGB-A317-A3055-101
    A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Lung cancer
    Paris
    BGB-LC-201
    A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    BI 1479-0008 (BEAMION LUNG 2)
    Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled,;multi-centre trial evaluating orally administered;BI 1810631 compared with standard of care as first-line treatment;in patients with unresectable, locally advanced or metastatic nonsquamous;non-small cell lung cancer harbouring HER2 tyrosine;kinase domain mutations.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    BI1438-0009 (DAREON 9)
    DAREONTM-9: A Phase Ib open-label dose escalation and dose;confirmation safety study of intravenous BI 764532 in;combination with topotecan for the treatment of patients with;small cell lung cancer

    PAULINE DU RUSQUEC

<
1 ...7
>